AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2020. The put-call ratio across all filers is 0.75 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $27,000 | -74.3% | 10,900 | -28.8% | 0.00% | – |
| Q1 2022 | $105,000 | +9.4% | 15,300 | +44.3% | 0.00% | – |
| Q1 2021 | $96,000 | -45.5% | 10,600 | -59.7% | 0.00% | -100.0% |
| Q4 2020 | $176,000 | -22.8% | 26,300 | -41.9% | 0.00% | 0.0% |
| Q3 2020 | $228,000 | -27.8% | 45,300 | +15.9% | 0.00% | -50.0% |
| Q2 2020 | $316,000 | -78.7% | 39,100 | -79.1% | 0.00% | -81.8% |
| Q1 2020 | $1,486,000 | +230.2% | 187,200 | +213.8% | 0.01% | +266.7% |
| Q4 2019 | $450,000 | +248.8% | 59,654 | +91.9% | 0.00% | +200.0% |
| Q3 2019 | $129,000 | +892.3% | 31,078 | +935.9% | 0.00% | – |
| Q3 2018 | $13,000 | -96.1% | 3,000 | -90.6% | 0.00% | -100.0% |
| Q3 2017 | $336,000 | +5.3% | 32,000 | +10.7% | 0.00% | 0.0% |
| Q2 2017 | $319,000 | +398.4% | 28,900 | +337.9% | 0.00% | – |
| Q1 2017 | $64,000 | – | 6,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |